Replimune

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Replimune and other ETFs, options, and stocks.

About REPL

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer.

CEO

Sushil Patel

CEOSushil Patel

Employees

479

Employees479

Headquarters

Woburn, Massachusetts

HeadquartersWoburn, Massachusetts

Founded

2015

Founded2015

Employees

479

Employees479

REPL Key Statistics

Market cap

453.90M

Market cap453.90M

Price-Earnings ratio

-1.74

Price-Earnings ratio-1.74

Dividend yield

—

Dividend yield—

Average volume

2.10M

Average volume2.10M

High today

$5.90

High today$5.90

Low today

$5.68

Low today$5.68

Open price

$5.76

Open price$5.76

Volume

1.06M

Volume1.06M

52 Week high

$17.00

52 Week high$17.00

52 Week low

$2.68

52 Week low$2.68

REPL News

TipRanks 1d

REPL Lawsuit Alert! Class Action Lawsuit Against Replimune Group

A class action lawsuit was filed against Replimune Group (REPL) by Levi & Korsinsky on July 24, 2025. The plaintiffs (shareholders) alleged that they bought REP...

Seeking Alpha 2d

Replimune gains as FDA to discuss path for rejected skin cancer drug

Healthcare On the Move Replimune gains as FDA to discuss path for rejected skin cancer drug Sep. 02, 2025 3:00 PM ET Replimune Group, Inc. (REPL) Stock BMY By:...

TipRanks 2d

Replimune announces Type A meeting scheduled with FDA

Replimune (REPL) Groupy announced that a Type A meeting with the U.S. Food and Drug Administration, FDA, has been scheduled to discuss the complete response let...

Analyst ratings

67%

of 9 ratings

Buy

22.2%

Hold

66.7%

Sell

11.1%

People also own

Based on the portfolios of people who own REPL. This list is generated using Robinhood data, and it’s not a recommendation.